Silexion Therapeutics Corp has announced the adjournment of its extraordinary general meeting, originally scheduled for October 19, 2026, to October 26, 2026. The meeting is crucial for the company as it seeks shareholder approval for two significant proposals that could impact its future.

The proposals include an increase in the authorized share capital by 500 million ordinary shares and a reverse share split at a ratio between 1-for-15 and 1-for-25. Both measures are designed to help Silexion comply with Nasdaq listing requirements, particularly regarding shareholder equity and share price.

Background

Silexion Therapeutics Corp is a clinical-stage biotechnology company focused on developing innovative treatments for solid tumor cancers driven by the mutated KRAS oncogene. The company is listed on the Nasdaq under the ticker symbols SLXN and SLXNW, and it operates under the SIC classification for Biological Products (No Diagnostic Substances) [2836]. Recent filings include a definitive proxy statement filed on October 5, 2026, and a recent 8-K filing on October 26, 2026.

What the Filing Says

According to the filing, the extraordinary general meeting was convened but adjourned without conducting any business. The meeting will reconvene to discuss:

Proposal 1 - Authorized Share Capital Increase Proposal: An increase to the authorized share capital of the Company by 500,000,000 ordinary shares.

Proposal 2 - Reverse Share Split Proposal: Authorization of the Board to effect a reverse share split of the Company’s ordinary shares.

Impact

The adjournment and subsequent proposals may affect Silexion's shareholders and its compliance with Nasdaq listing rules. The company aims to restore compliance with Nasdaq Listing Rule 5550(b)(1), which requires a minimum of $2.5 million in shareholders' equity, and Listing Rule 5550(a)(2), which mandates a minimum bid price of $1.00 per share.

What's Next

The reconvened extraordinary general meeting is set for October 26, 2026. Shareholders are urged to participate and vote on the proposals that could significantly influence the company's financial structure and market position.